Skip to main content

New resources available to accelerate the adoption of novel digital clinical measures in clinical research

Take the fast track to becoming a V3 and V3+ expert

Unlocking market access for diabetes management with sensor-based health data solutions

Over 1 in 11 Americans live with diabetes, a chronic condition that affects millions globally. Despite the rise of connected technologies and digital health innovations, there’s a disconnect between the data collected by these tools and their integration into clinical care and reimbursement pathways.

Even with advances like FDA clearance for over-the-counter continuous glucose monitors (CGMs), the disconnect between patient-generated health data (PGHD) and these connected devices still fails to inform clinical decisions and reimbursement pathways. This results in treatment gaps, inequities in care, and a healthcare system burdened by over $400 billion in annual costs.

To address these gaps, DATAcc by DiMe is convening industry leaders across the healthcare spectrum—including pharmaceutical and medical device manufacturers, payors, health systems, regulators, and patients—to create a clear path for integrating sensor-based health data to transform diabetes care.

By joining this project, you will:

  • Shape the future of diabetes care by building the industry’s first comprehensive framework for incorporating PGHD into care models, ensuring that sensor-based health data is used to improve patient outcomes
  • Develop policy recommendations that ensure the integration and commercial success of sensor-based digital health technologies (sDHTs) for monitoring and treatment decisions
  • Build relationships with key industry leaders and gather market insights from pharmaceutical companies, medical device developers, payors, health systems, and regulators

Name(Required)
This field is for validation purposes and should be left unchanged.

Join us!

By harnessing sensor-based PGHDs, such as continuous glucose monitors and other sensor-based digital health technologies (sDHTs), we can accelerate access to innovative treatments and improve health outcomes for millions of people living with diabetes.